Gholami Kheirollah, Ziaie Shadi, Shalviri Gloria
Department of Clinical Pharmacy. Faculty of Pharmacy, Tehran University of Medical Sciences . Tehran ( Iran ).
Iranian Adverse Drug Reaction Monitoring Center, Undersecretary for Food and Drug Affairs, Ministry of Health, Tehran ( Iran ).
Pharm Pract (Granada). 2008 Jan;6(1):51-5. doi: 10.4321/s1886-36552008000100008. Epub 2008 Mar 10.
Considering increased use of cardiovascular drugs and limitations in pre-marketing trials for drug safety evaluation, post marketing evaluation of adverse drug reactions (ADRs) induced by this class of medicinal products seems necessary.
To determine the rate and seriousness of adverse reactions induced by cardiovascular drugs in outpatients. To compare sex and different age groups in developing ADRs with cardiovascular agents. To assess the relationship between frequencies of ADRs and the number of drugs used.
This cross-sectional study was done in cardiovascular clinic at a teaching hospital. All patients during an eight months period were evaluated for cardiovascular drugs induced ADRs. Patient and reaction factors were analyzed in detected ADRs. Patients with or without ADRs were compared in sex and age by using chi-square test. Assessing the relationship between frequencies of ADRs and the number of drugs used was done by using Pearson analysis.
The total number of 518 patients was visited at the clinic. ADRs were detected in 105 (20.3%) patients. The most frequent ADRs were occurred in the age group of 51-60. The highest rate of ADRs was recorded to be induced by Diltiazem (23.5%) and the lowest rate with Atenolol (3%). Headache was the most frequent detected ADR (23%). Assessing the severity and preventability of ADRs revealed that 1.1% of ADRs were detected as severe and 1.9% as preventable reactions. Women significantly developed more ADRs in this study (chi square = 3.978, P<0.05). ADRs more frequently occurred with increasing age in this study (chi square = 15.871, P<0.05). With increasing the number of drugs used, the frequency of ADRs increased (Pearson=0.259, P<0.05).
Monitoring ADRs in patients using cardiovascular drugs is a matter of importance since this class of medicines is usually used by elderly patients with critical conditions and underlying diseases.
考虑到心血管药物使用的增加以及药物安全性评估上市前试验的局限性,对这类药品引起的药物不良反应(ADR)进行上市后评估似乎很有必要。
确定门诊患者中心血管药物引起的不良反应的发生率和严重程度。比较使用心血管药物发生ADR的性别和不同年龄组。评估ADR发生频率与用药数量之间的关系。
这项横断面研究在一家教学医院的心血管科进行。对八个月期间的所有患者进行心血管药物引起的ADR评估。对检测到的ADR中的患者和反应因素进行分析。使用卡方检验比较有或无ADR患者的性别和年龄。使用Pearson分析评估ADR发生频率与用药数量之间的关系。
该诊所共接诊518例患者。105例(20.3%)患者检测到ADR。最常见的ADR发生在51 - 60岁年龄组。ADR发生率最高的是地尔硫䓬(23.5%),最低的是阿替洛尔(3%)。头痛是最常检测到的ADR(23%)。评估ADR的严重程度和可预防性显示,1.1%的ADR被检测为严重,1.9%为可预防性反应。在本研究中,女性发生ADR的情况明显更多(卡方 = 3.978,P<0.05)。在本研究中,ADR随着年龄增长更频繁发生(卡方 = 15.871,P<0.05)。随着用药数量的增加,ADR的发生频率增加(Pearson = 0.259,P<0.05)。
监测使用心血管药物患者的ADR很重要,因为这类药物通常用于患有严重疾病和基础疾病的老年患者。